121
Participants
Start Date
July 27, 2022
Primary Completion Date
June 30, 2032
Study Completion Date
June 30, 2032
Biomarker based treatment (Temozolomide monotherapy or Radiotherapy monotherapy)
Temozolomide or Radiotherapy
Chemo-Radiotherapy consisting of 40 Gy in 15 daily fractions with concurrent temozolomide.
Temozolomide will be administered at a dose of 75 mg/m2 daily for a total of 21 days. This will be followed by adjuvant temozolomide (150-200 mg/m2 daily for 5 day
RECRUITING
Tom Baker Cancer Centre, Calgary
RECRUITING
Cross Cancer Institute, Edmonton
AHS Cancer Control Alberta
OTHER